Barclays downgraded shares of Moderna (NASDAQ:MRNA – Free Report) from an overweight rating to an equal weight rating in a report published on Tuesday, Ratings reports. The firm currently has $45.00 ...

Fintel reports that on February 18, 2025, Barclays downgraded their outlook for Moderna (NasdaqGS:MRNA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 78.68% Upside As of February 18 ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Moderna stock reversed losses on its fourth-quarter report after CEO Stephane Bancel deflected concerns over RFK Jr. Is MRNA ...

BofA analyst Tim Anderson lowered the firm’s price target on Moderna (MRNA) to $32 from $34 and keeps an Underperform rating on the shares.

Barclays downgraded Moderna (MRNA) to Equal Weight from Overweight with a price target of $45, down from $111, post the Q4 report. The firm ...

Read up on the latest Rear Window News, Reviews and Features from the team at Collider. Your comment has not been saved A photographer in a wheelchair spies on his neighbors from his Greenwich ...

The health care sector is likely reacting to the uncertainty created by the effect of federal budget cuts now being ...

Norovirus infection rates are extremely high this year, raising the question: Why can’t a vaccine protect us from the stomach ...

Kengo Kuma and Associates’ extension to Lisbon’s Centro de Arte Moderna is a gesture that bears no relation to the existing ...

The U.S. FDA has paused Moderna's norovirus vaccine trial due to a neurological side effect. Meanwhile, Robert F. Kennedy Jr.